Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Linda R Duska
Phase 1–2 Study of Docetaxel Plus Aflibercept in Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
The Lancet Oncology
Oncology
Related publications
Phase II Study of Bevacizumab and Pemetrexed for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
A Phase II Study of the Combination Chemotherapy of Bevacizumab and Gemcitabine in Women With Platinum-Resistant Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Journal of Ovarian Research
Gynecology
Oncology
Obstetrics
Erratum To: The New WHO Classification of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer and Its Clinical Implications
Archives of Gynecology and Obstetrics
Medicine
Gynecology
Obstetrics
Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial
Urology
Urology
Follow-Up of Patients Who Are Clinically Disease-Free After Primary Treatment for Fallopian Tube, Primary Peritoneal, or Epithelial Ovarian Cancer: A Program in Evidence-Based Care Guideline Adaptation
Current Oncology
Oncology
Ovarian Cancer May Originate in the Fallopian Tube
Cancer Discovery
Oncology
Phase II Evaluation of Dasatinib in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
Salpingo-Oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 Mutation
JAMA - Journal of the American Medical Association
Medicine
A Phase II Evaluation of Lapatinib in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
